Oncologists could use some education about testing for and targeting the major mutations in cholangiocarcinoma, according to survey results presented at the 2021 Gastrointestinal Cancers Symposium.
Targets are emerging to combat this challenging malignancy, and it is imperative that oncologists understand their importance, according to presenter Kinjal Parikh, PharmD, BCOP, the associate director of clinical strategy for Hematology/Oncology at Medscape